nidan7500 Monday, 06/03/19 09:24:48 AM Re: nidan7500 post# 195259 Post # of 238091 Quote:The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer's disease patients. Key performance measures will be collected over 6 months, at up to seven (7) sites in Australia. COGNISION™ is an easy to use, reliable system that provides physiological measures of cognitive processing ("cognitive biomarkers"). These biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of targeted drug effects. https://www.prnewswire.com/news-releases/neuronetrix-has-been-selected-by-anavex-life-sciences-corp-to-support-the-upcoming-phase-2a-clinical-trial-for-anavex-2-73-281898201.html This kind of science is the opposite of the old school DART BOARD.